Diabetes is a major complication for HAART regimens



Ever since their advent in the mid-nineties, HAART (or Highly Active Anti-Retroviral Treatment) medications have changed the way we look at HIV/AIDS today, allowing patients to live with the disease rather than die from it. But these life-saving medications come with a long list of side effects, which includes increased levels of cholesterol and triglycerides, lipodystrophy (abnormal redistribution of fat in/on the patients’ bodies), and also diabetes. 

Studies have shown that protease inhibitors (or PIs), a class of HAART regimens, are in particular linked to the developing of insulin resistance, and, therefore, to the developing or worsening of diabetes.